Advisory Research’s Evolent Health EVH Stock Holding History

Advisory Research’s Portfolio EVH Stock Details EVH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-50,354	Closed	-$1.37M	–	374
2023 Q3	$1.37M	Sell	50,354 -13,517	-21%	-$376K	0.19%	148
2023 Q2	$1.94M	Sell	63,871 -41,322	-39%	-$1.34M	0.25%	111
2023 Q1	$3.41M	Buy	105,193 +2,035	+2%	+$64.4K	0.56%	43
2022 Q4	$2.9M	Sell	103,158 -76,492	-43%	-$2.19M	0.27%	60
2022 Q3	$6.46M	Sell	179,650 -4,630	-3%	-$163K	0.63%	35
2022 Q2	$5.66M	Sell	184,280 -14,224	-7%	-$414K	0.55%	38
2022 Q1	$6.41M	Buy	198,504 +84,077	+73%	+$2.2M	0.51%	41
2021 Q4	$3.17M	Buy	114,427 +34,669	+43%	+$995K	0.25%	72
2021 Q3	$2.47M	Buy	+79,758	New	+$1.91M	0.16%	114
2017 Q3	–	Sell	-86,739	Closed	-$2.2M	–	442
2017 Q2	$2.2M	Buy	+86,739	New	+$2.09M	0.03%	208

Other funds holding EVH

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Advisory Research's EVH Position: Q4 2023 in Review

Advisory Research sold out of Evolent Health (EVH) in Q4 2023, closing a stake of 50,354 shares — an estimated $1.37M sold.

Advisory Research first reported a position in EVH in Q2 2017 and held it in 10 quarters. The position peaked at $6.46M in Q3 2022. 234 funds tracked by Wall St. Rank hold EVH as of Q4 2023.

Advisory Research reported no remaining Evolent Health position as of Q4 2023 after selling out during the quarter.
Advisory Research sold 50,354 Evolent Health shares in Q4 2023, an estimated $1.37M.
Advisory Research first reported a position in Evolent Health in Q2 2017 and held it in 10 quarters.
Advisory Research's Evolent Health position peaked at $6.46M in Q3 2022.
234 funds tracked by Wall St. Rank held Evolent Health as of Q4 2023.

Based on Advisory Research's 13F filing for Q4 2023, filed 13 Feb 2024.